Michael Waisbourd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Waisbourd has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Anat Loewenstein
4 shared publicationsIgal Leibovitch
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
3 shared publicationsMichaella Goldstein
3 shared publicationsAnat Kesler
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
2 shared publicationsA Loewenstein
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel
1 shared publicationA Rabinovitch
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel
1 shared publication
Latest Publications
- Open Access
- 12 May 2017
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 10 (5) , 738-741
Implantation of trabecular micro-bypass stent using a novel “landing strip” technique
To describe a novel technique of creating a landing strip within the trabecular meshwork to guide trabecular micro-bypass stent (iStent) implantation in patients who underwent phacoemulsification. Thirty-four eyes from 30 patients who underwent iStent implantation after phacoemulsification from May 2014 to February 2015 were included in our retrospective study. All iStents were implanted via the "landing strip" technique. A 25-gauge microvitreoretinal blade was used to bisect the trabecular meshwork to less than 1 clock-hour, effectively creating a landing strip. The iStent applicator was pressed along the landing strip and then the stent was released into the trabecular meshwork. Of the 34 eyes with iStent implantation, 27 (79.4%) eyes had primary open-angle glaucoma, 6 (17.6%) eyes had pseudoexfoliation glaucoma, and 1 (2.9%) eye had ocular hypertension. At 6-month follow-up (n=17), the mean number of hypotensive medications decreased from 2.2±1.2 at baseline to 0.8±1.3 (P=0.05) and mean intraocular pressure decreased from 19.7±4.1 mm Hg at baseline to 16.7±2.1 mm Hg (P=0.58). Two eyes (5.9%) required subsequent trabeculectomy. The "landing strip" technique appears to be an effective way to assist with iStent implantation.
- 12 May 2017
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 10 (5) , 738-741
Open AccessImplantation of trabecular micro-bypass stent using a novel “landing strip” technique
To describe a novel technique of creating a landing strip within the trabecular meshwork to guide trabecular micro-bypass stent (iStent) implantation in patients who underwent phacoemulsification. Thirty-four eyes from 30 patients who underwent iStent implantation after phacoemulsification from May 2014 to February 2015 were included in our retrospective study. All iStents were implanted via the "landing strip" technique. A 25-gauge microvitreoretinal blade was used to bisect the trabecular meshwork to less than 1 clock-hour, effectively creating a landing strip. The iStent applicator was pressed along the landing strip and then the stent was released into the trabecular meshwork. Of the 34 eyes with iStent implantation, 27 (79.4%) eyes had primary open-angle glaucoma, 6 (17.6%) eyes had pseudoexfoliation glaucoma, and 1 (2.9%) eye had ocular hypertension. At 6-month follow-up (n=17), the mean number of hypotensive medications decreased from 2.2±1.2 at baseline to 0.8±1.3 (P=0.05) and mean intraocular pressure decreased from 19.7±4.1 mm Hg at baseline to 16.7±2.1 mm Hg (P=0.58). Two eyes (5.9%) required subsequent trabeculectomy. The "landing strip" technique appears to be an effective way to assist with iStent implantation.
- 1 December 2011
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 113 (10) , 839-843
OCT assessment of morphological changes of the optic nerve head and macula in idiopathic intracranial hypertension
- 1 December 2011
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 113 (10) , 839-843
OCT assessment of morphological changes of the optic nerve head and macula in idiopathic intracranial hypertension
- 1 May 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (5) , 598-599
Conjunctival Lymphoma in a Child
Purpose: To evaluate the quality of stromal bed and the safety on endothelium in preparation of donor tissue for Descemet stripping automated endothelial keratoplasty in a masked fashion using 2 mechanical microkeratomes and a femtosecond laser. Methods: Deep anterior lamellar dissection was performed on 15 donor corneas. Central endothelial cell density was calculated using specular microscopy before and after the dissection. One cornea from each of 5 donor pairs was cut with the Moria ALTK system with the CBm microkeratome using the 300-μm head and the mate cut with the Horizon disposable 300-μm microkeratome. Five additional donor corneas were cut with the Intralase 60-kHz FS laser. The donor corneas were then bisected with half of the cornea used for Live/Dead assay to study central endothelial viability. The other halves were sent for scanning electron microscopy of the stromal bed. Qualitative surface roughness of the scanning electron microscopy images was graded by 2 masked observers, and quantitative surface roughness was assessed using roughness evaluation software. Results: The Horizon group showed a smoother stromal bed compared with the Moria or Intralase groups by 2 masked observers. However, the Moria group had the smoothest quantitative score of all the groups when assessed by roughness evaluation software. There was no statistically significant difference among the 3 groups in the percentage change in the central endothelial cell density or percentage of viable central endothelium by Live/Dead assay after the dissection. Conclusions: Both mechanical microkeratomes created smoother stromal bed dissections than the femtosecond laser. All systems provided good endothelial cell viability.
- 1 May 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (5) , 598-599
Conjunctival Lymphoma in a Child
Purpose: To evaluate the quality of stromal bed and the safety on endothelium in preparation of donor tissue for Descemet stripping automated endothelial keratoplasty in a masked fashion using 2 mechanical microkeratomes and a femtosecond laser. Methods: Deep anterior lamellar dissection was performed on 15 donor corneas. Central endothelial cell density was calculated using specular microscopy before and after the dissection. One cornea from each of 5 donor pairs was cut with the Moria ALTK system with the CBm microkeratome using the 300-μm head and the mate cut with the Horizon disposable 300-μm microkeratome. Five additional donor corneas were cut with the Intralase 60-kHz FS laser. The donor corneas were then bisected with half of the cornea used for Live/Dead assay to study central endothelial viability. The other halves were sent for scanning electron microscopy of the stromal bed. Qualitative surface roughness of the scanning electron microscopy images was graded by 2 masked observers, and quantitative surface roughness was assessed using roughness evaluation software. Results: The Horizon group showed a smoother stromal bed compared with the Moria or Intralase groups by 2 masked observers. However, the Moria group had the smoothest quantitative score of all the groups when assessed by roughness evaluation software. There was no statistically significant difference among the 3 groups in the percentage change in the central endothelial cell density or percentage of viable central endothelium by Live/Dead assay after the dissection. Conclusions: Both mechanical microkeratomes created smoother stromal bed dissections than the femtosecond laser. All systems provided good endothelial cell viability.
- 1 March 2011
- Vol. 13 (3) , 141-6
National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
Intravitreal injections of the anti-vascular endothelial growth factor (VEGF) drugs bevacizumab (Avastin) and ranibizumab (Lucentis) became the mainstay of treatment for various retinal pathologies, but there is no consensus among ophthalmologists on the precise use of these drugs. To describe the routine practices of retinal specialists in Israel regarding anti-VEGF drug treatment. A questionnaire was sent via email to all 62 members of the Israeli Society of Retinal Specialists. The survey included 34 questions on various aspects of the use of anti-VEGF drugs: diagnosis, treatment, follow-up of different retinal pathologies, and the measures taken for ensuring sterile administration of the intravitreal injections. Fifty members (80%) completed the survey. Most of them (56%) offered both bevacizumab and ranibizumab to their patients for age-related macular degeneration, but 70% were influenced by the patient's socioeconomic status. Three consecutive monthly injections were usually recommended (58%) for the first 3 months, and treatment was extended as long as subretinal or intraretinal fluids persisted (57%). Over two-thirds (68%) switched the drugs after the 3-monthly series if the first one yielded no improvement in fluid status. The routine practice for intravitreal injection (> 80%) involved the wearing of sterile gloves, using an eyelid speculum, and administering povidone-iodine pretreatment and topical antibiotics after treatment. Intravitreal VEGF administration varies widely among Israeli retinal specialists. The current survey is intended to assist Israeli ophthalmologists in establishing their own treatment strategy for patients with retinal pathologies.
- 1 March 2011
- Vol. 13 (3) , 141-6
National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
Intravitreal injections of the anti-vascular endothelial growth factor (VEGF) drugs bevacizumab (Avastin) and ranibizumab (Lucentis) became the mainstay of treatment for various retinal pathologies, but there is no consensus among ophthalmologists on the precise use of these drugs. To describe the routine practices of retinal specialists in Israel regarding anti-VEGF drug treatment. A questionnaire was sent via email to all 62 members of the Israeli Society of Retinal Specialists. The survey included 34 questions on various aspects of the use of anti-VEGF drugs: diagnosis, treatment, follow-up of different retinal pathologies, and the measures taken for ensuring sterile administration of the intravitreal injections. Fifty members (80%) completed the survey. Most of them (56%) offered both bevacizumab and ranibizumab to their patients for age-related macular degeneration, but 70% were influenced by the patient's socioeconomic status. Three consecutive monthly injections were usually recommended (58%) for the first 3 months, and treatment was extended as long as subretinal or intraretinal fluids persisted (57%). Over two-thirds (68%) switched the drugs after the 3-monthly series if the first one yielded no improvement in fluid status. The routine practice for intravitreal injection (> 80%) involved the wearing of sterile gloves, using an eyelid speculum, and administering povidone-iodine pretreatment and topical antibiotics after treatment. Intravitreal VEGF administration varies widely among Israeli retinal specialists. The current survey is intended to assist Israeli ophthalmologists in establishing their own treatment strategy for patients with retinal pathologies.
- 2 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (3) , 203-207
Treatment of diabetic retinopathy with anti‐VEGF drugs
: The aim of this review is to summarize the latest developments in the treatment of diabetic retinopathy (DR) with anti‐vascular endothelial growth factor (VEGF) drugs. We reviewed recent studies that evaluated the role of the anti‐VEGF agents bevacizumab, ranibizumab and pegaptanib in the treatment of DR. There was only one large randomized controlled trial that evaluated the role of ranibizumab in diabetic macular oedema (DME). Other prospective and retrospective studies provided important insight into the role of anti‐VEGF drugs in DR, but most of them were not conducted in large scales. The growing evidence indicates that anti‐VEGF drugs are beneficial in DR, especially in DME. Further studies are needed to fully evaluate the role of these agents, especially in proliferative DR and in DR candidates for vitrectomy surgery.
- 2 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (3) , 203-207
Treatment of diabetic retinopathy with anti‐VEGF drugs
: The aim of this review is to summarize the latest developments in the treatment of diabetic retinopathy (DR) with anti‐vascular endothelial growth factor (VEGF) drugs. We reviewed recent studies that evaluated the role of the anti‐VEGF agents bevacizumab, ranibizumab and pegaptanib in the treatment of DR. There was only one large randomized controlled trial that evaluated the role of ranibizumab in diabetic macular oedema (DME). Other prospective and retrospective studies provided important insight into the role of anti‐VEGF drugs in DR, but most of them were not conducted in large scales. The growing evidence indicates that anti‐VEGF drugs are beneficial in DR, especially in DME. Further studies are needed to fully evaluate the role of these agents, especially in proliferative DR and in DR candidates for vitrectomy surgery.
- 1 September 2010
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 20 (5) , 902-906
Comparison of the Transpalpebral Tonometer TGDc-01 with Goldmann Applanation Tonometry
Purpose: This study aimed to compare intraocular pressure (IOP) measurements obtained by the transpalpebral tonometer TGDc-01 and by the Goldmann applanation tonometer (GAT). Methods: IOP was measured by the conventional GAT and the TGDc-01 tonometer. Central corneal thickness (CCI) was measured for all eyes. Results: Sixty-seven consecutive patients (123 eyes) participated. The mean difference between the 2 techniques (TGDc-01-GAT) was −0.93 mmHg, SD=2.74 (p=0.0002, paired t-test), and 70% of the measurements were within ±2 mmHg. The correlation coefficient was 0.67 (p<0.0001). A subgroup analysis according to CCT was conducted. For CCT <520 μm, the mean IOP difference was 0.67 mmHg (p=0.13); r=0.75 (p<0.001). For CCT 520 μm-580 μm, the mean IOP difference was −1.08 mmHg (p=0.001); r=0.69 (p580 μm, the mean IOP difference was −2.29 mmHg (p=0.0003); r=0.57 (p=0.003). Conclusions: TGDC-01 may estimate IOP with a fair agreement to the Goldmann tonometer, although caution should be used for patients who require precise IOP measurements. TGDc-01 measured higher IOPs than Goldman tonometry for thinner corneas, a trend that was reversed for thicker corneas. This tonometer is a portable device, easy to use, does not require anesthetic drops, and may be suitable for IOP screening.
- 1 September 2010
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 20 (5) , 902-906
Comparison of the Transpalpebral Tonometer TGDc-01 with Goldmann Applanation Tonometry
Purpose: This study aimed to compare intraocular pressure (IOP) measurements obtained by the transpalpebral tonometer TGDc-01 and by the Goldmann applanation tonometer (GAT). Methods: IOP was measured by the conventional GAT and the TGDc-01 tonometer. Central corneal thickness (CCI) was measured for all eyes. Results: Sixty-seven consecutive patients (123 eyes) participated. The mean difference between the 2 techniques (TGDc-01-GAT) was −0.93 mmHg, SD=2.74 (p=0.0002, paired t-test), and 70% of the measurements were within ±2 mmHg. The correlation coefficient was 0.67 (p<0.0001). A subgroup analysis according to CCT was conducted. For CCT <520 μm, the mean IOP difference was 0.67 mmHg (p=0.13); r=0.75 (p<0.001). For CCT 520 μm-580 μm, the mean IOP difference was −1.08 mmHg (p=0.001); r=0.69 (p580 μm, the mean IOP difference was −2.29 mmHg (p=0.0003); r=0.57 (p=0.003). Conclusions: TGDC-01 may estimate IOP with a fair agreement to the Goldmann tonometer, although caution should be used for patients who require precise IOP measurements. TGDc-01 measured higher IOPs than Goldman tonometry for thinner corneas, a trend that was reversed for thicker corneas. This tonometer is a portable device, easy to use, does not require anesthetic drops, and may be suitable for IOP screening.
- 17 March 2009
- Published by Wolters Kluwer Health in Neurology
- Vol. 72 (11) , 1027
Postinfectious ocular flutter
- 17 March 2009
- Published by Wolters Kluwer Health in Neurology
- Vol. 72 (11) , 1027
Postinfectious ocular flutter
- 16 March 2007
- Published by Springer Nature in Eye
- Vol. 21 (7) , 998-999
Awareness and the use of nutritional supplementation for age-related macular degeneration patients
- 16 March 2007
- Published by Springer Nature in Eye
- Vol. 21 (7) , 998-999
Awareness and the use of nutritional supplementation for age-related macular degeneration patients
- 1 January 2007
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (8) , 643-662
Targeting Vascular Endothelial Growth Factor
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. While treatment options for advanced AMD have been rather limited until recently, the introduction of intravitreal injections of anti-angiogenic agents appears to be a promising and revolutionary mode of treatment for this blinding disease. Vascular endothelial growth factor (VEGF) appears to play a pivotal role in the pathogenesis of choroidal neovascularisation, one of the cornerstones of advanced AMD. Pegaptanib, the first anti-VEGF treatment approved for AMD patients, is a VEGF-neutralising aptamer that specifically inhibits one isoform of VEGF (VEGF-165). Although evidence suggested that pegaptanib was superior to previous treatment options, results with this agent were still unsatisfactory. Ranibizumab is a humanised anti-VEGF monoclonal antibody fragment that inhibits all isotypes of VEGF. This new drug has demonstrated a high efficacy profile in terms of inhibiting disease progression and even improving visual acuity. Bevacizumab is a full-length anti-VEGF antibody that was originally approved for use in metastatic colon cancer and is under investigation as a low-cost off-label alternative for patients with AMD. There is growing evidence that this drug may be an effective and safe alternative to the more expensive ranibizumab, although prospective multicentre trials are required to fully investigate this issue. Undoubtedly, the concept of directly injecting anti-VEGF drugs into the vitreal cavity brings new hope to many AMD patients.
- 1 January 2007
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (8) , 643-662
Targeting Vascular Endothelial Growth Factor
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. While treatment options for advanced AMD have been rather limited until recently, the introduction of intravitreal injections of anti-angiogenic agents appears to be a promising and revolutionary mode of treatment for this blinding disease. Vascular endothelial growth factor (VEGF) appears to play a pivotal role in the pathogenesis of choroidal neovascularisation, one of the cornerstones of advanced AMD. Pegaptanib, the first anti-VEGF treatment approved for AMD patients, is a VEGF-neutralising aptamer that specifically inhibits one isoform of VEGF (VEGF-165). Although evidence suggested that pegaptanib was superior to previous treatment options, results with this agent were still unsatisfactory. Ranibizumab is a humanised anti-VEGF monoclonal antibody fragment that inhibits all isotypes of VEGF. This new drug has demonstrated a high efficacy profile in terms of inhibiting disease progression and even improving visual acuity. Bevacizumab is a full-length anti-VEGF antibody that was originally approved for use in metastatic colon cancer and is under investigation as a low-cost off-label alternative for patients with AMD. There is growing evidence that this drug may be an effective and safe alternative to the more expensive ranibizumab, although prospective multicentre trials are required to fully investigate this issue. Undoubtedly, the concept of directly injecting anti-VEGF drugs into the vitreal cavity brings new hope to many AMD patients.